MeiraGTx Holdings plc (NASDAQ:MGTX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The US$537m market-cap company announced a latest loss of US$148m on 31 December 2024 for its most recent financial year result. Many investors are wondering about the rate at which MeiraGTx Holdings will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.
Consensus from 3 of the American Biotechs analysts is that MeiraGTx Holdings is on the verge of breakeven. They expect the company to post a final loss in 2025, before turning a profit of US$20m in 2026. Therefore, the company is expected to breakeven just over a year from today. How fast will the company have to grow each year in order to reach the breakeven point by 2026? Working backwards from analyst estimates, it turns out that they expect the company to grow 43% year-on-year, on average, which is rather optimistic! If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
Given this is a high-level overview, we won’t go into details of MeiraGTx Holdings' upcoming projects, though, keep in mind that generally biotechs, depending on the stage of product development, have irregular periods of cash flow. So, a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
View our latest analysis for MeiraGTx Holdings
Before we wrap up, there’s one issue worth mentioning. MeiraGTx Holdings currently has a debt-to-equity ratio of 108%. Typically, debt shouldn’t exceed 40% of your equity, which in this case, the company has significantly overshot. A higher level of debt requires more stringent capital management which increases the risk around investing in the loss-making company.
This article is not intended to be a comprehensive analysis on MeiraGTx Holdings, so if you are interested in understanding the company at a deeper level, take a look at MeiraGTx Holdings' company page on Simply Wall St. We've also put together a list of important factors you should look at:
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.